Loading
Lymphoma was the first cancer shown to be caused by a virus, the first common cancer sorted into subtypes by reading which genes were switched on, and the first in which a patient's own immune cells were reprogrammed to cure them. This roadmap follows the evidence from 1958 to the trials reading out in 2032.
Lymphoma has been first at more things than any other cancer, and the reason is that you can get hold of it. A lymph node is easy to biopsy, the cells grow in culture, the disease circulates in blood, and it responds to treatment fast enough that a trial reads out in years rather than decades.
That is why the first human tumour virus was found in it. Denis Burkitt described a jaw tumour in Ugandan children in 1958 and mapped where it occurred; Epstein, Achong and Barr saw virus particles in cells cultured from one of his biopsies in 1964. Twenty years later the first human retrovirus, now called human T-lymphotropic virus type 1, was isolated from the lymphocytes of a patient with a T-cell lymphoma by Poiesz and Gallo, and tied to adult T-cell leukaemia across a Japanese population by Hinuma.
It is also why lymphoma was the first common cancer taken apart by gene expression. Alizadeh and Staudt showed in 2000 that diffuse large B-cell lymphoma is at least two diseases; Rosenwald turned that into a survival predictor in 2002; Hans gave pathology laboratories a three-stain version in 2004. The genetic classifications followed in 2018, when Chapuy and Schmitz published five clusters and four subtypes within three weeks of each other, and Wright's LymphGen tool in 2020 made it possible to classify one patient's tumour with a probability attached.
Treatment moved on three tracks. In Hodgkin lymphoma the whole effort since the 1990s has been to take treatment away without losing the cure, because the Dutch cohorts showed that 48.5 per cent of survivors develop a second cancer within 40 years and 50 per cent develop cardiovascular disease. HD10 halved the chemotherapy and cut the radiation dose; HD18 and AHL2011 used the scan after two cycles to shorten or soften the intensive regimen; HD16 and EORTC H10 tried to drop radiotherapy on a clear scan and could not. In aggressive B-cell lymphoma, R-CHOP has survived every challenger except one: obinutuzumab failed in GOYA, dose-adjusted EPOCH-R failed in CALGB 50303, ibrutinib failed overall in PHOENIX, and only polatuzumab vedotin in POLARIX improved on it. In indolent lymphoma the question has been how long to treat rather than how hard, and PRIMA answered it with six extra years before relapse and no change in survival.
The last decade belongs to the immune treatments. ZUMA-1, JULIET and TRANSCEND NHL 001 made CAR-T a third line in large B-cell lymphoma; ZUMA-7 and TRANSFORM moved it to second line, while BELINDA failed in the same setting with a 52-day manufacturing wait. ELARA and ZUMA-5 brought it to follicular lymphoma. The CD20 bispecific antibodies arrived alongside, off the shelf and without apheresis, and inMIND, ELM-2 and ROSEWOOD show the relapsed indolent setting is now crowded with options.
What has not been solved: the genetic subtypes have not yet changed a single first-line treatment, the T-cell lymphomas have almost no randomised evidence at all, no trial has shown that acting on a circulating tumour DNA result improves anything, and the drugs that cure this disease are unavailable to most of the people who get it.
Denis Burkitt described a tumour involving the jaws in African children in 1958 and mapped where it occurred; the geography pointed at an infectious cause. In 1964 Epstein, Achong and Barr saw virus particles in lymphoblasts cultured from one of his biopsies, the first virus ever found in a human tumour, and the start of the field that now includes human papillomavirus, hepatitis B and C, Helicobacter pylori and human herpesvirus 8. Neither paper has an abstract indexed on Europe PMC, so no figure from them is quoted here. The second virus came from the other side of the lymphoid system. Poiesz, Gallo and colleagues isolated type C retrovirus particles from the lymphocytes of a patient with a T-cell lymphoma in 1980, the first human retrovirus, characterising a reverse transcriptase that preferred magnesium to manganese and six particle proteins unlike those of any known primate retrovirus. The year after, Hinuma's group in Japan found antibodies to a related antigen in all 44 patients with adult T-cell leukaemia they tested, in 26 per cent of healthy adults from endemic areas and in almost none from elsewhere. Human T-lymphotropic virus type 1 is now screened for in blood donations.
The clinical description that set off the search for a cancer virus. It is also an argument for geographic epidemiology: Burkitt found the cause by asking where the disease was, not by looking down a microscope.
The start of viral oncology. Everything in cancer prevention that works by preventing or treating an infection, from hepatitis B vaccination to Helicobacter eradication for gastric MALT lymphoma, descends from the idea this paper established.
The first human retrovirus, and the start of the line of work that identified HIV three years later. For lymphoma it means that adult T-cell leukaemia/lymphoma has a known, transmissible, preventable cause, and that screening blood donors and advising on breastfeeding in endemic areas are cancer prevention measures.
The seroepidemiology that tied a virus to a cancer across a population rather than in one patient. It is the reason blood donations are screened for human T-lymphotropic virus type 1 in Japan and elsewhere, and the reason breastfeeding advice is part of cancer prevention in endemic regions.
Hodgkin lymphoma was curable before anyone knew what it was made of, and by the 1990s the question had become how much treatment could be removed. HD10 answered it for early favourable disease, randomising 1,370 patients in a two by two design and finding no difference between four and two cycles of ABVD (five-year freedom from treatment failure 93.0 against 91.1 per cent, p = 0.39) or between 30 Gy and 20 Gy of involved-field radiotherapy (p = 1.00). Two cycles with 20 Gy became the standard, and the four-cycle, 30 Gy group had the most toxicity. The reason the question mattered arrived in full later. The Dutch cohorts measured what cure costs: 48.5 per cent of survivors developed a second cancer within 40 years, with risk still raised at 35 years, and 50 per cent developed cardiovascular disease, with coronary heart disease and heart failure still four to six times the population rate after 35 years. The second-cancer risk did not fall for patients treated between 1989 and 2000 compared with those treated in the 1960s and 1970s, despite the less toxic protocols introduced in between.
Alizadeh and Staudt showed in 2000 that diffuse large B-cell lymphoma contains at least two diseases that look identical under the microscope. Rosenwald profiled 240 biopsies in 2002, found germinal-centre, activated and type 3 subgroups, and built a 17-gene survival predictor independent of the International Prognostic Index; the stromal and immune signatures in that paper anticipated the tumour microenvironment era. Hans put the classification within reach of ordinary pathology in 2004, using CD10, BCL6 and MUM1 to split 152 cases into germinal-centre and non-germinal-centre groups with five-year survival of 76 against 34 per cent. Then the field stalled. The classification predicted outcome but did not direct treatment, and the trials that selected patients by it, PHOENIX among them, failed. The genetic classifications of 2018 were the answer to why: Chapuy's five clusters from 304 tumours and Schmitz's four subtypes from 574 both cut the disease finer than the stain could, and Schmitz's MCD and BN2 subtypes carried a mechanism, chronic active B-cell receptor signalling, with a drug class already in the clinic. Wright's LymphGen tool in 2020 turned cohort clustering into a probability for one patient's tumour, and extended the classification to seven subtypes that share genetics with indolent and extranodal lymphomas.
R-CHOP has been the first-line standard for aggressive B-cell lymphoma since rituximab was added to CHOP, and almost nothing has improved on it. CALGB 50303 compared dose-adjusted EPOCH-R, which many centres had adopted on single-arm evidence, and found no difference in progression-free or overall survival with substantially more febrile neutropenia, mucositis and neuropathy. GOYA substituted obinutuzumab in 1,418 patients and got a hazard ratio of 0.92 with more grade 3 to 5 and fatal adverse events, despite the same substitution working in follicular lymphoma and chronic lymphocytic leukaemia. REMARC added two years of lenalidomide maintenance and delayed progression without extending life. PHOENIX added ibrutinib and failed overall, helping patients under 60 and harming those over 60 by stopping them finishing the chemotherapy. What worked was subtraction and substitution rather than addition. FLYER showed that four cycles of R-CHOP with two extra rituximab doses was non-inferior to six in young patients with low-risk limited-stage disease, at three-year progression-free survival of 96 per cent and roughly a quarter fewer adverse events. POLARIX replaced vincristine with polatuzumab vedotin and improved progression-free survival, the only first-line improvement in two decades.
Four large trials asked the same question from different directions: can a positron emission tomography scan after two cycles of chemotherapy decide what happens next. The answer turned out to be asymmetric. Intensifying on a positive scan works. EORTC H10 switched scan-positive early-stage patients from ABVD to escalated BEACOPP with involved-node radiotherapy and raised five-year progression-free survival from 77.4 to 90.6 per cent. De-escalating on a negative scan works for chemotherapy. HD18 shortened escalated BEACOPP from six or eight cycles to four in scan-negative advanced disease with five-year progression-free survival of 92.2 against 90.8 per cent and half the severe infections; AHL2011 switched scan-negative patients to ABVD after two cycles of escalated BEACOPP with five-year progression-free survival of 85.7 against 86.2 per cent and grade 3 to 4 anaemia falling from 69 to 28 per cent. RATHL had already shown that bleomycin could be dropped after a negative scan in advanced disease. De-escalating on a negative scan does not work for radiotherapy. HD16 omitted 20 Gy after a negative scan and lost 7.3 percentage points of five-year progression-free survival; H10 could not demonstrate non-inferiority in either risk group, and in the favourable group five-year progression-free survival was 99.0 per cent with radiotherapy against 87.1 per cent without.
Follicular lymphoma is treated in episodes across decades, so the questions are about duration and sequence rather than intensity. PRIMA randomised 1,018 responders to two years of rituximab maintenance or observation and reported median progression-free survival of 10.5 against 4.1 years at nine years, with ten-year overall survival of about 80 per cent in both arms: the cleanest demonstration in lymphoma that delaying progression and extending life are different things. Casulo gave the field the marker that matters. Of 588 patients given first-line R-CHOP, 19 per cent progressed within two years, and their five-year overall survival was 50 per cent against 90 per cent, with an index-adjusted hazard ratio of 6.44. That group now triggers a repeat biopsy, because transformation is the commonest cause, and goes to treatment that does not depend on chemotherapy sensitivity. For the rest of the disease the options multiplied. GALLIUM and RELEVANCE changed the first line; ELARA and ZUMA-5 brought CAR-T, with complete responses in 69 and 74 per cent; ELM-2 and the other CD20 bispecific antibodies brought off-the-shelf alternatives, with a 73.4 per cent complete response rate for odronextamab; ROSEWOOD paired a Bruton tyrosine kinase inhibitor with a type II antibody; inMIND added a CD19 antibody to lenalidomide and rituximab for a progression-free survival hazard ratio of 0.43. In marginal zone lymphoma, IELSG-19 remains the only randomised first-line systemic trial.
ZUMA-1, JULIET and TRANSCEND NHL 001 established CD19 CAR-T in large B-cell lymphoma after two or more lines between 2017 and 2020, with objective responses in 73 per cent and complete responses in 53 per cent in the largest of them, and grade 3 or worse cytokine release syndrome in 2 per cent for lisocabtagene maraleucel against much higher rates for the other products. Then the three products split in the second line. ZUMA-7 and TRANSFORM both beat salvage chemotherapy with an autologous transplant. BELINDA, testing tisagenlecleucel in the same setting, did not: median event-free survival was 3.0 months in both arms. The explanation most often offered is the 52-day median interval from leukapheresis to infusion, during which 25.9 per cent of the CAR-T group progressed against 13.8 per cent of the standard-care group, compounded by a baseline imbalance that favoured the comparator. It is a cross-trial inference, and the fact that it is the best available explanation for a 322-patient randomised failure says something about how the field measures what it is doing. The CD20 bispecific antibodies arrived alongside and solved the logistics rather than the biology: no apheresis, no manufacturing wait, available the week the decision is made. STARGLO, EPCORE NHL-1, POLARGO and ECHELON-3 between them now give transplant-ineligible relapsed diffuse large B-cell lymphoma four options with randomised or pivotal evidence where a decade ago it had none.
LyMa established three years of rituximab maintenance after autologous transplantation in patients under 66, with four-year event-free survival of 79 against 61 per cent and an overall survival benefit, which is rare for a maintenance strategy in lymphoma. For older patients the question became where to put the Bruton tyrosine kinase inhibitor. SHINE added ibrutinib to bendamustine-rituximab and gained 28 months of progression-free survival (80.6 against 52.9 months, hazard ratio 0.75) with no survival difference. ECHO repeated the design with acalabrutinib and gained 17 months (66.4 against 49.6, hazard ratio 0.73), again with no survival difference and grade 3 or greater adverse events in roughly 89 per cent of both arms. ENRICH took the opposite route and removed the chemotherapy: ibrutinib with rituximab beat immunochemotherapy with an adjusted hazard ratio of 0.69, driven almost entirely by the comparison against R-CHOP (0.37) rather than against bendamustine-rituximab (0.91). TRIANGLE meanwhile asked whether the autologous transplant is still needed in younger patients when ibrutinib is added to induction and maintenance. Taken together, the four trials mean a person over 60 with mantle cell lymphoma now has a chemotherapy-free first-line option, and that nobody has yet shown any of these strategies makes them live longer.
Two trials carry most of the randomised evidence for the T-cell lymphomas, and one of them is not randomised. JCOG9801 is the only controlled trial ever run exclusively in adult T-cell leukaemia/lymphoma: 118 patients, a complete response rate of 40 against 25 per cent for an intensive Japanese regimen over biweekly CHOP, three-year overall survival of 24 against 13 per cent that did not reach significance on two-sided testing, and grade 4 thrombocytopenia in 74 against 17 per cent. SMILE is a 38-patient single-arm phase 2 that made extranodal NK/T-cell lymphoma treatable, with an overall response rate of 79 per cent and one-year overall survival of 55 per cent, by building the regimen on asparaginase rather than on an anthracycline. ECHELON-2 is the exception that shows what is possible: brentuximab vedotin with CHP improved survival in CD30-positive peripheral T-cell lymphoma in a global double-blind randomised trial. ALCANZA did the same for cutaneous T-cell lymphoma. Everything else, including the choice of first-line regimen in peripheral T-cell lymphoma not otherwise specified, rests on single-arm studies and registry series. Several randomised trials are recruiting at last, in peripheral T-cell lymphoma with the T follicular helper phenotype and in NK/T-cell disease.
The Hodgkin de-escalation question gets its best-designed attempt yet. RADAR (NCT04685616, 1,042 estimated participants; recruiting) randomises ABVD against A2VD, which replaces the bleomycin with brentuximab vedotin, and omits radiotherapy entirely in anyone with a Deauville score of 1 to 3 after two cycles; primary completion is listed for September 2030. The oldest patients with diffuse large B-cell lymphoma finally get their own trials. POLAR BEAR (NCT04332822, 300 estimated participants; recruiting) tests polatuzumab vedotin in place of vincristine in R-miniCHOP in people aged 80 or over, or 75 or over and frail by a geriatric assessment, with a primary completion date of 28 December 2025 that has now passed. ARCHED (NCT05820841, 330 estimated participants; recruiting) adds acalabrutinib to R-miniCHOP, with primary completion listed for February 2029. The bispecific antibodies move to the front. A National Cancer Institute trial (NCT06337318, 600 estimated participants; recruiting) compares mosunetuzumab with rituximab as first treatment for low tumour burden follicular lymphoma, with primary completion listed for 31 March 2032, and a European trial (NCT06006117, 260 estimated participants; recruiting) runs mosunetuzumab with lenalidomide against the investigator's choice in relapsed marginal zone lymphoma, primary completion September 2027. In primary central nervous system lymphoma, PRIMA-CNS (NCT06830421, 340 estimated participants; recruiting) compares conventional immunochemotherapy with a short induction and an autologous transplant in elderly patients, primary completion 31 August 2029. FORTplus (NCT05045664, 100 estimated participants; recruiting) tests whether an anti-CD20 antibody makes a 4 Gy radiotherapy dose safe in early follicular lymphoma, primary completion 30 September 2027.
First, the genetics have not reached the clinic. Three classifications and a probabilistic tool exist, and not one first-line treatment decision anywhere is made by genetic subtype outside a trial. The gap between Schmitz in 2018 and a trial that assigns treatment by LymphGen is the clearest unfinished business in the disease. Second, nothing acts on a blood test. Circulating tumour DNA predicts outcome at diagnosis, detects residual disease better than imaging, reads cell of origin from plasma and flags transformation before it declares itself, and no randomised trial has yet shown that changing treatment on the strength of it helps anyone. Third, the T-cell lymphomas have almost no randomised evidence, and the diseases concentrated in east Asia, the Caribbean, west Africa and Latin America have least of all. Adult T-cell leukaemia/lymphoma has had exactly one controlled trial, in 1998. Fourth, access. Rituximab transformed B-cell lymphoma in 1997 and is still unavailable or unaffordable in much of the world; asparaginase, which makes NK/T-cell lymphoma treatable, is intermittently supplied; CAR-T requires an apheresis service, a cryopreservation chain and a centre able to manage cytokine release syndrome. The treatments on this page cure a higher proportion of people with lymphoma than of any other common cancer, in the places that have them.
The piece that turns a research classification into something a trial can use on one person's biopsy, with a probability attached rather than a flat label. It is the reason genetics-directed lymphoma trials became possible at all.
The paper that established lymphoma as the solid-tumour field where circulating tumour DNA works best, because the mutations are many and the tumour sheds. It underpins the response-adapted trial designs now being built on molecular rather than radiographic response.
The Japanese standard regimen for aggressive adult T-cell leukaemia/lymphoma rests on this trial. Three-year overall survival of 24 per cent with the better arm is the plainest statement of how much room remains, and is why allogeneic transplantation, mogamulizumab and antiviral approaches have all been pursued since.
Every era's records, trial outcomes and papers, and every watch item, as JSON.
Readouts, decisions and registry completion dates ahead. Each date is quoted from its source, not inferred; a missing date means no source states one.
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Loading this step…
The 48 most recent of 60 papers; see them all →
An option with a demonstrated survival benefit for transplant-ineligible relapsed diffuse large B-cell lymphoma, a group for whom very little has ever shown one. The fatal adverse event imbalance belongs in the conversation alongside the survival figure.
A new combination for relapsed or refractory follicular lymphoma that adds a CD19-directed antibody to the established lenalidomide and rituximab pairing, with the largest progression-free survival hazard ratio reported in the setting.
A second randomised confirmation that adding a Bruton tyrosine kinase inhibitor to first-line bendamustine-rituximab delays progression in older patients with mantle cell lymphoma, with a toxicity profile that did not improve as much as the drug's selectivity promised.
The evidence behind the United States approval of brentuximab vedotin with lenalidomide and a rituximab product for relapsed or refractory diffuse large B-cell lymphoma after two or more lines in patients not eligible for an autologous transplant or CAR-T. It is also the first demonstration that a CD30-directed conjugate helps in a disease where CD30 expression is variable.
The authors' conclusion is that ibrutinib-rituximab should be considered a new standard-of-care option for first-line treatment of older patients with mantle-cell lymphoma. The subgroup split means it is clearly better than R-CHOP and roughly equivalent to bendamustine-rituximab.
For fit younger patients treated in the intensive German tradition, BrECADD replaces escalated BEACOPP; how it compares with nivolumab-AVD from S1826 is the open question.
An off-the-shelf alternative to CAR-T for repeatedly relapsed follicular lymphoma: no apheresis, no manufacturing wait, and a complete response rate in the same range, at the cost of continued treatment rather than a single infusion.
Ibrutinib during induction and as maintenance should be part of first-line treatment for younger patients with mantle cell lymphoma; whether transplant adds anything to an ibrutinib-containing regimen is still being followed.
Shares GHSG HD10: reduced treatment intensity in early-stage favourable Hodgkin lymphoma, RATHL: adapted treatment guided by interim PET-CT in advanced Hodgkin lymphoma, GHSG HD21: PET-guided BrECADD versus escalated BEACOPP in advanced-stage classical Hodgkin lymphoma, Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER).
Shares Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER), RELEVANCE, TROG 99.03, Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03.
Shares Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER), RELEVANCE, TROG 99.03, Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03.
Shares GHSG HD21: PET-guided BrECADD versus escalated BEACOPP in advanced-stage classical Hodgkin lymphoma, ZUMA-1, Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER), RELEVANCE.
Shares Tafasitamab, Polatuzumab vedotin, Lisocabtagene maraleucel, Mosunetuzumab.
Shares Franck Morschhauser, Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial, REMARC, Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line R-CHOP.
Shares LyMa, PRIMA-CNS, Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma, POLARGO.
Shares ZUMA-1, ZUMA-5, Odronextamab, TRANSFORM.